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Although the transmissible spongiform encephalopathies (TSEs) are neurodegenerative diseases, their
agents usually replicate and accumulate in lymphoid tissues long before infection spreads to the central
nervous system (CNS). Studies of a mouse scrapie model have shown that mature follicular dendritic cells
(FDCs), which express the host prion protein (PrPc), are critical for replication of infection in lymphoid
tissues. In the absence of mature FDCs, the spread of infection to the CNS is significantly impaired. Tumor
necrosis factor alpha (TNF-) secretion by lymphocytes is important for maintaining FDC networks, and
signaling is mediated through TNF receptor 1 (TNFR-1) expressed on FDCs and/or their precursors. A
treatment that blocks TNFR signaling leads to the temporary dedifferentiation of mature FDCs, raising the
hypothesis that a similar treatment would significantly delay the peripheral pathogenesis of scrapie. Here,
specific neutralization of the TNFR signaling pathway was achieved through treatment with a fusion protein
consisting of two soluble human TNFR (huTNFR) (p80) domains linked to the Fc portion of human immu-
noglobulin G1 (huTNFR:Fc). A single treatment of mice with huTNFR:Fc before or shortly after intraperito-
neal injection with the ME7 scrapie strain significantly delayed the onset of disease in the CNS and reduced
the early accumulation of disease-specific PrP in the spleen. These effects coincided with a temporary dedif-
ferentiation of mature FDCs within 5 days of huTNFR:Fc treatment. We conclude that treatments that
specifically inhibit the TNFR signaling pathway may present an opportunity for early intervention in periph-
erally transmitted TSEs.
The transmissible spongiform encephalopathies (TSEs), or
“prion diseases,” are infectious neurodegenerative diseases
that affect humans and both wild and domestic animals. The
host prion protein (PrPc) is critical for TSE agent replication
(8) and accumulates in diseased tissues as an abnormal, deter-
gent-insoluble, relatively proteinase-resistant isoform, PrPSc
(4). Although the precise nature of the TSE agent is uncertain
(13), PrPSc copurifies with infectivity and is considered to be a
major component of the infectious agent (41).
Natural TSEs, including sheep scrapie, bovine spongiform
encephalopathy (BSE), chronic wasting disease in mule deer
and elk, and variant Creutzfeldt-Jakob disease (vCJD) in hu-
mans, are considered to be acquired peripherally. For example,
the emergence of vCJD in the United Kingdom population is
almost certainly due to consumption of BSE-contaminated
tissues (7). Following peripheral exposure, TSE agents usually
accumulate in lymphoid tissues long before infection spreads
to the central nervous system (CNS). For example, after intra-
gastric or oral challenge of rodents with scrapie, the infectious
agent first accumulates in Peyer’s patches and gut-associated
lymphoid tissues (2, 24). The detection of PrPSc in Peyer’s
patches and gut-associated lymphoid tissues of sheep with nat-
ural scrapie (1, 20) prior to detection in other lymphoid tissues
and the CNS (46) implies that this disease is also acquired
orally. Lymphoid tissues play an important role in transmission
in some TSE models (17), but this tissue tropism may be agent
strain dependent. Although acquired peripherally, BSE in cat-
tle (43) and iatrogenic Creutzfeldt-Jakob disease in humans
(21) appear to be confined to nervous tissues. However, within
the lymphoid tissues of patients with vCJD (21) and most
sheep with natural scrapie (45) or following experimental pe-
ripheral infection of rodents with scrapie (5, 29, 30, 33), early
PrPSc accumulation takes place on follicular dendritic cells
(FDCs). Studies of mouse scrapie models have shown that
mature FDCs are critical for replication in lymphoid tissues
and that in their absence, neuroinvasion following peripheral
challenge is significantly impaired (5, 29, 30, 35). From the
lymphoid tissues, infectious agents spread to the CNS via pe-
ripheral nerves (19).
The FDC therefore presents a potential target for therapeu-
tic intervention in peripherally acquired TSEs such as natural
sheep scrapie and vCJD. Indeed, recent studies have demon-
strated that treatments that temporarily interfere with the in-
tegrity (29, 35) or function (28) of FDCs also interfere with
TSE pathogenesis. Signaling through lymphocyte-derived tu-
mor necrosis factor alpha (TNF-) is critical for FDC devel-
opment, as mice deficient in TNF- (TNF-/ mice) lack
mature FDCs in lymphoid tissues (38). The effects of TNF-
on FDC development are mediated via signaling through TNF
receptor 1 (TNFR-1) expressed on FDCs and/or their precur-
sors (44). Specific neutralization of the TNF- signaling path-
way leads to the temporary inactivation of FDCs (31), suggest-
ing that FDCs require constant stimulation from this cytokine
to maintain their differentiated state. It has previously been
shown that in the absence of mature FDCs in the lymphoid
tissues of TNF-/ mice, susceptibility to peripheral chal-
lenge with scrapie is reduced (30). Therefore, in this study we
sought to determine whether a treatment that temporarily
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blocks the TNF- signaling pathway would delay the spread of
scrapie to the CNS.
MATERIALS AND METHODS
huTNFR:Fc treatment. At the times indicated, C57BL mice (8 to 12 weeks
old) were given a single intraperitoneal (i.p.) injection of 100 g of a dimeric
fusion protein containing the soluble human TNFR (huTNFR) (p80) domain
linked to the Fc portion of human immunoglobulin G1 (huTNFR:Fc; Immunex
Corp., Seattle, Wash.) (34) or 100 g of polyclonal human immunoglobulin G
(hu-Ig) (Sandoglobulin; provided by J. Browning, Biogen Inc., Cambridge,
Mass.) as a control. To monitor the effects of treatment on FDC status, at the
times indicated following treatment, two spleens were taken from each group
and halved. One half was fixed in periodate-lysine-paraformaldehyde and em-
bedded in paraffin wax for immunocytochemical detection of PrP (33) with the
PrP-specific antiserum 1B3 (15). The other half was snap-frozen at the temper-
ature of liquid nitrogen, and 6-m-thick sections were cut on a cryostat. FDCs
were visualized by staining with the FDC-specific monoclonal antiserum
FDC-M2 (27) or 8C12 monoclonal antiserum to detect CD35 (Pharmingen, San
Diego, Calif.). Immunolabeling was carried out with alkaline phosphatase cou-
pled to the avidin-biotin complex (Vector Laboratories Inc., Burlingame, Calif.).
Vector Red (Vector Laboratories) was used as a substrate.
Scrapie infection. At the times indicated relative to treatment, mice were
injected intracerebrally (i.c.) or i.p. with 20 l of a 1.0, 0.1, or 0.01% (wt/vol)
dilution of unspun brain homogenate from C57BL mice terminally affected with
ME7 scrapie (20 l of a 1.0% homogenate represents a dose of approximately 1
 104.5 i.c. 50% infectious dose [ID50] units). Following challenge, animals were
coded and assessed weekly for signs of clinical disease and killed at a standard
clinical end point (16). Scrapie diagnosis was confirmed by histopathological
assessment of vacuolation in the brain. Where indicated, some mice were sacri-
ficed 70 days postchallenge, and their spleens were taken for further analysis. For
the bioassay of scrapie infectivity, individual half spleens were prepared as 10%
(wt/vol) homogenates in physiological saline and 20 l was injected i.c. into
groups of 12 C57BL indicator mice. The scrapie titer in each spleen was deter-
mined from the mean incubation period for the assay mice with reference to
established dose-incubation period response curves for scrapie-infected spleen
tissue (11).
Immunoblot detection of PrPSc. The remaining half of each spleen collected 70
days postchallenge was prepared as previously described (12, 28, 30). In brief,
before immunoblot analysis, spleen tissue homogenates were treated with 20 g
of proteinase K (to confirm the presence of PrPSc) and subsequently partially
purified by treatment with 2% (wt/vol) N-lauroylsarcosine (in 0.1 M Tris [pH
7.4]), allowing sedimentation of only the proteinase-K-resistant, detergent-insol-
uble fraction of PrP (PrPSc). Samples were subjected to electrophoresis through
sodium dodecyl sulfate–12% polyacrylamide gels (Bio-Rad, Hemel Hempstead,
United Kingdom) and transferred to polyvinylidene difluoride membranes (Bio-
Rad) by semidry blotting. PrP was detected with the PrP-specific rabbit poly-
clonal antiserum 1B3 (15) followed by alkaline phosphatase-conjugated goat
anti-rabbit antiserum (Jackson ImmunoResearch Laboratories Inc., West Grove,
Pa.), and bound alkaline phosphatase activity was detected with SigmaFast NBT/
BCIP solution (Sigma, Poole, Dorset, United Kingdom).
Ultrastructural immunohistochemistry. Spleen fragments were immersion
fixed in 0.5% paraformaldehyde–0.5% glutaraldehyde for 24 h at 4°C, postfixed
in osmium tetroxide, dehydrated, and embedded in araldite. Serial 65-nm-thick
sections were then placed on 300-mesh nickel grids and prepared as previously
described (23). Briefly, PrP was detected by staining with the PrP-specific rabbit
polyclonal antiserum 1A8 (14) followed by Auroprobe 1-nm colloidal gold.
Sections were then postfixed in 2.5% glutaraldehyde in phosphate-buffered sa-
line, and staining was enhanced with immunogold silver stain. The grids were
then counterstained with uranyl acetate and lead citrate.
Previous studies have shown that the combination of fixatives and pretreat-
ments required for the preparation of tissue for electron microscopy by this
method destroys PrPc immunoreactivity and reveals only disease-specific PrP
accumulations (23).
Statistical analysis. Incubation period data are expressed as means standard
errors of the mean, and significant differences between incubation periods were
sought by one-way analysis of variance with Minitab for Windows (Minitab Inc.,
State College, Pa.).
RESULTS
Effect of huTNFR:Fc treatment on FDC status. A blockade
of the TNF- signaling pathway was achieved by a single i.p.
injection of 100 g of huTNFR:Fc (34). This fusion protein
binds TNF- with high affinity and acts as an antagonist of
TNF- biological activity in in vivo assays in mice (34, 47).
Here, within 2 days of treatment of mice with huTNFR:Fc, a
significant reduction in staining for the FDC markers FDC-M2
and CD35 was observed in lymphoid follicles of the spleen
(Fig. 1). Furthermore, FDC-M2 and CD35 expression was
absent 5 (data not shown) and 7 (Fig. 1) days after treatment
with huTNFR:Fc. The cellular isomer of the prion protein,
PrPc, is expressed by FDCs in uninfected mice (Fig. 1) (5, 29,
33). Likewise, PrPc expression was also markedly reduced
within 2 days of treatment and undetectable 5 (data not shown)
and 7 (Fig. 1) days after treatment with huTNFR:Fc. The
effects of huTNFR:Fc treatment on FDC status were tempo-
rary, as PrP-expressing FDC networks were detected in the
spleen 14 days after treatment (Fig. 1). Treatment of mice with
100 g of polyclonal hu-Ig as a control had no adverse effect on
FDC status (Fig. 1). In some follicles from hu-Ig-treated mice,
there appeared to be increases in the size of the FDC network
and the level of PrPc expression 14 days after treatment com-
pared to values for follicles analyzed 2 and 7 days after treat-
ment (Fig. 1). This may be indicative of a germinal-center
response to hu-Ig.
Ultrastructural analysis of the effect of huTNFR:Fc treat-
ment on FDC status. Mice were treated with huTNFR:Fc or
hu-Ig 38 days after i.p. injection with scrapie, and PrP deposi-
tion in the spleen was analyzed 7 days later by light-microscop-
ical and ultrastructural immunohistochemical methods. As
expected, in spleens of control-treated mice, abundant disease-
specific PrP staining in association with FDCs was detected by
light microscopy (Fig. 2a and c). Immunoelectron microscopic
analysis confirmed that these PrP accumulations were disease
specific and were found in association with electron-dense ma-
terial at the surface of highly convoluted FDC dendrites (Fig.
2e and f), as previously reported (23). In some follicles, indi-
vidual fibrils consistent with the dimensions of amyloid fibrils
were present in association with FDCs (data not shown). Dis-
ease-specific PrP accumulations were also detected within sec-
ondary lysosomes of tingible body macrophages (Fig. 2e).
Mice were treated with huTNFR:Fc 38 days after scrapie
injection, and abundant PrP labeling was still apparent in the
spleen 7 days after treatment (Fig. 2d) despite a temporary
absence of mature FDCs (Fig. 2b). Ultrastructural analysis
revealed that the centers of secondary lymphoid follicles in
spleens from huTNFR:Fc-treated mice showed marked degen-
erative changes compared with those from hu-Ig-treated con-
trol mice. Severe and extensive lymphocyte apoptosis was
noted (Fig. 2g), and large numbers of highly reactive macro-
phages containing degenerative cellular material were also
present in these sites (Fig. 2h). In many cases, whole apoptotic
B lymphocytes could also be identified within these macro-
phages. At the ultrastructural level, FDC networks were iden-
tified but their processes appeared immature (Fig. 2i) and
lacked the highly convoluted characteristics observed for those
of hu-Ig-treated control mice (Fig. 2f). The immature nature of
these FDC dendrites was consistent with the loss of expression
of FDC-specific markers following huTNFR:Fc treatment
(Fig. 1 and 2). Although a few mature FDC processes were
identified at the ultrastructural level, it was not possible to
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determine whether these were regenerating FDCs or mature
FDCs unaffected by the TNFR signaling blockade (31).
Effect of huTNFR:Fc treatment on scrapie pathogenesis.
Mice were given a single i.p. injection of huTNFR:Fc (or hu-Ig
as a control) at one of three different times relative to scrapie
challenge: 5 days before scrapie injection, so mature FDCs
would be absent in lymphoid tissues at the time of scrapie
injection; 14 days after scrapie injection, soon after the onset of
scrapie replication in lymphoid tissues; or 38 days after scrapie
injection, when high levels of scrapie infectivity are present in
lymphoid tissues (5, 30). When groups of six mice were chal-
lenged with the ME7 scrapie strain by direct i.c. injection into
the CNS, treatment with huTNFR:Fc 5 days before or 14 days
after scrapie challenge had no effect on the incubation period
of the disease (164 to 172 days; Fig. 3a) or pathology within
the brain (data not shown) compared with those of controls.
These findings demonstrate that the blockade of the TNFR
signaling pathway did not affect scrapie pathogenesis once
disease was established in the CNS.
When treated with huTNFR:Fc before or shortly after pe-
ripheral (i.p.) injection with scrapie, mice developed neurolog-
ical disease much later than did the hu-Ig-treated controls. The
most significant effect was observed when mice were treated 5
days before i.p. scrapie injection (Fig. 3b). For example, fol-
lowing injection with a moderate dose of scrapie (20 l of a
1.0% scrapie brain homogenate), all control-treated mice suc-
cumbed to disease, with a mean incubation period of 255  15
days (n  8), whereas those treated with huTNFR:Fc devel-
oped disease 47 days later, with a mean incubation period of
302 7 days (P	 0.01; n 8; Fig. 3b). Likewise, when treated
with huTNFR:Fc before injection with a 10-fold-lower scrapie
dose (20 l of a 0.1% scrapie brain homogenate), mice devel-
oped neurological disease with a mean incubation period of
353  4 days (n  9), which was 38 days longer than the mean
incubation period of the hu-Ig-treated controls (315  7 days;
P 	 0.001; n  9; Fig. 3b). Despite these highly significant
prolongations of the incubation period, little effect on disease
susceptibility was observed following treatment with hu-
TNFR:Fc prior to injection with a low dose of scrapie (20 l of
a 0.01% scrapie brain homogenate): 7 of 9 huTNFR:Fc-treated
mice remained free of scrapie disease 500 days after inocula-
tion, compared to 5 of 9 control mice (Fig. 3b).
An increase in survival time was also observed when treat-
ment with huTNFR:Fc was delayed until 14 days after i.p.
injection with a moderate dose of scrapie (Fig. 3c). In this
instance, mice developed neurological disease with a mean
incubation period of 281  7 days (n  8), which was 19 days
longer than the mean incubation period of the hu-Ig-treated
controls (262  8.0 days; n  8). However, treatment with
huTNFR:Fc 38 days after injection, a time when high levels of
infectivity agents have already accumulated in the spleen (5,
FIG. 1. Effect of huTNFR:Fc treatment on FDC status in spleens of uninfected mice. Tissues were taken on the indicated days postinjection
(d.p.i.) with hu-Ig (control) or huTNFR:Fc, and adjacent frozen sections were stained with FDC-M2 monoclonal antiserum to detect FDCs (upper
row; red) or with 8C12 monoclonal antiserum to detect CD35 (middle row; red). PrP was detected on paraffin-embedded sections with the
PrP-specific polyclonal antiserum 1B3 (bottom row; red). Expression of FDC-M2, CD35, and PrP in the spleen was undetectable 7 days after
treatment with huTNFR:Fc. Original magnification, 400.
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30), had no effect on the incubation period compared with that
of control-treated mice (Fig. 3c).
Scrapie infectivity and PrPSc accumulation in the spleen.
Within 70 days of a peripheral injection of untreated mice with
the ME7 scrapie strain, high levels of infectivity and the dis-
ease-specific isomer of the prion protein, PrPSc, accumulate
within lymphoid tissues (5, 12, 28, 30). In this study, spleens
were taken from each control and huTNFR:Fc treatment
group 70 days after i.p. injection with a moderate dose of
scrapie and halved. PrPSc accumulation was determined in one
half by immunoblot analysis, while the scrapie infectivity titer
was estimated in the other half by bioassay in groups of indi-
cator mice. As expected, all spleens from control mice treated
with hu-Ig 5 days before or 14 or 38 days after scrapie chal-
lenge contained high infectivity titers (5.0 to 5.3 log i.c. ID50/g,
as estimated by incubation period assay; Fig. 4) and abundant
detergent-insoluble, relatively proteinase-K-resistant PrPSc
(Fig. 4). However, following treatment of mice with huTN-
FR:Fc 5 days before scrapie challenge, PrPSc was less abundant
in the spleen 70 days postinfection (Fig. 4a, lanes 4 and 6). In
contrast, the infectivity titers were as high as those detected in
spleens from hu-Ig-treated controls, suggesting that the accu-
mulation of PrPSc in the spleen lags behind replication of
infectivity during the early stages of infection, as observed in
previous studies (12, 28).
When treatment was delayed until 14 or 38 days after scrapie
challenge, no differences in the accumulation of infectivity or
abundance of PrPSc in the spleen were detected between con-
trol- and huTNFR:Fc-treated mice when measured 70 days
after scrapie challenge (Fig. 4b and c).
FIG. 2. Immunohistological analysis of the effects of huTNFR:Fc treatment on FDC status and PrP labeling in spleens of mice already
incubating scrapie. (a to d) Light-microscopical analysis. Mice were injected i.p. with scrapie and 38 days later given a single i.p. injection of
huTNFR:Fc (b and d) or hu-Ig as a control (a and c). Spleens were obtained 7 days later; frozen sections were stained for FDCs with FDC-M2
monoclonal antiserum (a and b; red), and PrP was detected on paraffin-embedded sections with the PrP-specific polyclonal antiserum 1B3 (c and
d; red). Abundant abnormal PrP was detected in association with FDCs in the spleens of control mice 45 days after scrapie injection. However,
when mice were treated with huTNFR:Fc 38 days after scrapie injection, heavy PrP labeling was still apparent in the spleen 7 days after treatment
despite a temporary absence of FDC-M2 expression. The arrow in panel D indicates a tingible body macrophage containing apoptotic B
lymphocytes. Magnification,400. (e to i) Ultrastructural analysis. Mice were injected i.p. with scrapie and 38 days later given a single i.p. injection
of huTNFR:Fc (g to i) or hu-Ig as a control (e and f). Spleens were obtained 7 days later, and araldite sections were immunostained with the
PrP-specific polyclonal antiserum 1A8. (e) An area of immunogold reactivity (indicated with an asterisk) is present between lymphocytes in the
germinal center of a scrapie-injected, hu-Ig-treated control mouse. This focal immunoreaction is associated with a complex knot of mature FDC
processes. Part of a tingible body macrophage is present at the bottom left (arrow). Bar  1.76 m. (f) High magnification of the FDC complex
indicated with an asterisk in panel e. Highly convoluted FDC processes are associated with the immunogold reaction. Many short linear and
curvilinear structures are immunolabeled. Bar  0.35 m. (g) Edge of a germinal center showing marked apoptosis (black arrows) in the spleen
of a scrapie-injected, huTNFR:Fc-treated mouse. Immature FDC dendritic processes surround the germinal center (white arrows). Bar 1.87 m.
(h) Tingible body macrophage (arrow) in the spleen of a scrapie-injected, huTNFR:Fc-treated mouse showing intralysosomal PrP accumulation.
Moderately reactive FDC dendrites lie adjacent to the macrophage. Bar  1.31 m. (i) Foci of immunoreactivity associated with immature FDC
dendritic processes in the spleen of a scrapie-injected, huTNFR:Fc-treated mouse. The immunogold reaction is associated with electron-dense
material in the extracellular space surrounding FDC dendrites. Bar  0.56 m.
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FIG. 2—Continued.
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DISCUSSION
Here we have shown that a single treatment of mice with
huTNFR:Fc before or shortly after a peripheral scrapie injec-
tion significantly extended survival time compared to that of
control-treated mice. Our studies also demonstrated that treat-
ment prior to peripheral exposure decreased the early accu-
mulation of disease-specific PrPSc within the spleen. These
effects coincided with a temporary dedifferentiation of mature
PrP-expressing FDCs in the spleen following treatment with
huTNFR:Fc. Taken together, these results are consistent with
previous findings that in the absence of mature FDCs in lym-
phoid tissues, neuroinvasion following peripheral injection
with scrapie is impaired (5, 29, 30). Surprisingly, a single treat-
ment with huTNFR:Fc had little influence on disease suscep-
tibility following low-dose scrapie challenge. Nevertheless,
TNF- blockade over longer periods may present a potential
strategy for intervention in peripherally acquired TSEs.
Secretion of TNF- has been implicated in the development
of neuropathology in several human inflammatory, infectious,
and autoimmune disorders (40). Although TNF- expression
has been reported to occur in the brains of mice showing
clinical signs of scrapie (9), studies using TNF-/ mice (30)
and TNFR-1-deficient mice (25) suggest that this cytokine
signaling pathway alone is not directly involved in the devel-
opment of neuropathology in TSEs. Due to its high molecular
weight, huTNFR:Fc would be unlikely to cross the blood-brain
FIG. 3. Blockade of the TNFR signaling pathway significantly extends the incubation period of disease following peripheral injection with ME7
scrapie. (a) Mice were treated with huTNFR:Fc () or hu-Ig as a control () 5 days before or 14 days after i.c. injection with a moderate dose
of scrapie (1.0% [wt/vol] scrapie brain homogenate). (b) Mice were treated with huTNFR:Fc () or hu-Ig as a control () 5 days before i.p.
injection with a moderate (1.0%) or limiting (0.1% or 0.01%) dose of scrapie. E, incubation periods for individual mice. (c) Mice were treated with
huTNFR:Fc () or hu-Ig () 5 days before or 14 or 38 days after i.p. injection with a moderate dose of scrapie. Each bar represents a mean 
standard error of the mean for six to nine mice. The vertical broken line represents the time at which two spleens were taken from each treatment
group for subsequent analysis of scrapie infectivity and PrPSc accumulation (see Fig. 4). d, days.
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barrier and inhibit TNF- signaling within the brain. Treat-
ment with huTNFR:Fc in this study had no effect on survival
time or neuropathology when mice were injected with scrapie
directly into the CNS, confirming that the effects of treatment
on TSE pathogenesis operate at a peripheral stage prior to
neuroinvasion. Our studies suggest this is most likely due to a
temporary interference with the integrity of FDCs, although
effects of huTNFR:Fc treatment on other cell types in the
spleen cannot be entirely excluded. However, the increased
survival time following treatment with huTNFR:Fc 14 days
after scrapie injection (Fig. 3b) and the recent demonstration
that membrane lymphotoxin, not TNF-, regulates the migra-
tion of dendritic cells in the spleen (48) suggest that it is
unlikely that the effects of huTNFR:Fc treatment on scrapie
pathogenesis are due to impaired cell trafficking from the site
of scrapie challenge to the spleen.
Light-microscopical analysis demonstrated that mature PrP-
expressing FDCs were temporarily absent in the spleen soon
after treatment with huTNFR:Fc. Several hypotheses could
explain the fate of FDCs following huTNFR:Fc treatment: (i)
FDCs temporarily revert to an immature state that affects their
function and phenotype; (ii) the chemokine gradients respon-
sible for the organization of cell populations within the germi-
nal center are altered (36), and as a consequence the FDCs
disperse; or (iii) in the absence of stimulation from TNF-,
FDCs undergo apoptosis. We consider the first hypothesis
most likely, as despite a temporary absence of FDC-M2, CD35,
and PrPc expression by FDCs, immature FDC processes were
detected at the ultrastructural level, suggesting that these cells
had reverted to a dedifferentiated state. Antigens are trapped
and retained on the surface of FDCs through interactions
between complement components and cellular complement
receptors (37, 39). The loss of expression of complement re-
ceptor 1 (CD35; Fig. 1) and substantially decreased abundance
of complement component C3 (data not shown) in lymphoid
follicles of treated mice implied that these immature FDC
processes had an impaired ability to retain antigens (31). Re-
cent studies have demonstrated that C1q, C3, and complement
receptors play an important role in the localization of TSE
infectious agents to FDCs (26, 28). Therefore, it is unlikely that
during the period of dedifferentiation following treatment with
huTNFR:Fc, these immature FDC processes would have the
potential to acquire TSE infectivity. Occasionally a few mature
FDC processes were detected in the spleen by ultrastructural
analysis 7 days after treatment (data not shown). These may
represent FDCs in the process of regeneration, but it is also
plausible that these were FDCs that were participating in
strong antigenic responses and whose state of differentiation
was unaffected by treatments which inhibit the TNFR signaling
pathway (31).
Ultrastructural analysis of secondary lymphoid follicles from
huTNFR:Fc-treated mice revealed other associated degenera-
tive changes. FDCs provide important costimulatory factors
which prevent B lymphocytes from undergoing apoptosis (18).
Therefore, the detection of severe and extensive lymphocyte
apoptosis following treatment with huTNFR:Fc suggested that
this was most likely due to a loss of mature FDCs. Many of
these apoptotic B lymphocytes were identified whole within
tingible body macrophages which scavenge apoptotic lympho-
cytes and are considered to regulate the germinal-center reac-
tion (42). The increased survival time following treatment with
huTNFR:Fc is unlikely to be directly related to a loss of B
lymphocytes by apoptosis, as ME7 scrapie pathogenesis is un-
affected in mice with impaired germinal-center B-lymphocyte
development (30). However, the effects of treatment on dis-
ease susceptibility could be indirectly related to a loss of cyto-
kine stimuli from B lymphocytes, which leads to FDC dedif-
ferentiation.
Within 70 days of a peripheral injection of immunocompe-
tent mice with the ME7 scrapie strain, high levels of infectivity
FIG. 4. PrPSc accumulation and infectivity titers in the spleen 70 days after i.p. injection with scrapie. Immunoblots show the accumulation of
detergent-insoluble, relatively proteinase-K-resistant PrPSc. Treatment of tissue in the presence () or absence () of proteinase K before
electrophoresis is indicated. Following proteinase K treatment, a typical three-band pattern was observed between molecular mass values of 20 and
30 kDa, representing unglycosylated, monoglycosylated, and diglycosylated isomers of PrP (in order of increasing molecular mass). Scrapie
infectivity titers are expressed as log i.c. ID50 units per gram. Mice were treated with hu-Ig (control) or huTNFR:Fc 5 days before (a) or 14 (b) or
38 (c) days after scrapie injection. Lane M contained molecular mass markers. d, days; PK, proteinase K.
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titers and abundant PrPSc are detected in the spleen (5, 12, 28,
30). Here, when mice were given huTNFR:Fc before scrapie
challenge, low levels of PrPSc were detected in the spleen 70
days postinoculation, approximately 50 days after the expected
reappearance of mature FDCs. In the absence of mature FDCs
at the time of scrapie challenge, it is likely that PrPSc and
infectivity from the inoculum persist in the spleen but that a
significant proportion is destroyed, for example by macro-
phages (3, 10). This effect would significantly delay both the
onset of replication when the FDCs reappear within 14 days of
treatment and the subsequent transfer of infectivity via periph-
eral nerves (19) into the CNS. Interestingly, infectivity titers in
spleens from huTNFR:Fc-treated mice were the same as those
from hu-Ig-treated controls, implying that the accumulation of
PrPSc in the spleen lags behind the replication of infectivity
during the early stages of infection (28). These experiments
also suggest that the time interval during which the FDCs were
unable to acquire and replicate scrapie was insufficient to allow
macrophages adequate time to destroy most of the infectious
agents, as huTNFR:Fc treatment had little, if any, effect on
disease susceptibility.
Further experiments will show whether it is possible to ex-
tend the period of FDC dedifferentiation beyond that de-
scribed in this report through prolonged treatment with mul-
tiple doses of huTNFR:Fc. Such an approach may reduce the
accumulation of scrapie infectivity in the spleen and further
delay or prevent the development of disease in the CNS. How-
ever, a prolonged blockade of proinflammatory cytokines such
as TNF- may cause serious side effects, including increased
susceptibility to other infectious microorganisms, increased in-
cidence of malignancies, or induction of autoimmune disease.
A therapeutic blockade of TNF- has been used to successfully
treat rheumatoid arthritis and Crohn’s disease in humans,
where this cytokine plays a critical role in mediating inflam-
mation (22, 32). The experience of long-term treatment of
human rheumatoid arthritis patients with TNF- antagonists
suggests that they are safe and well tolerated (22, 32).
The detection of infectivity in lymphoid tissues and of PrPSc
in association with FDCs from patients with vCJD (6, 21) and
sheep with natural scrapie (1, 20, 45) suggests that these TSEs
also share a similar requirement for FDCs. Therefore, the
experiments described in this report and those of others sug-
gest that treatments which temporarily interfere with the in-
tegrity (29, 35) or immune complex trapping function (28) of
FDCs offer a potential approach for early intervention in pe-
ripherally acquired TSEs.
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